Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and
safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China.